Home
Live Updates
Guselkumab Demonstrates Long-Term Benefit for Crohn Disease : comparemela.com
Guselkumab Demonstrates Long-Term Benefit for Crohn Disease
During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.
Related Keywords
Jan Wehkamp ,
Anita Afzali ,
Uc Health Anita Afzali ,
Johnson ,
University Of Cincinnati College Medicine ,
Johnson Innovative Medicines ,
United European Gastroenterology Week ,
Cincinnati College ,
Johnson Innovative ,
Severely Active Crohn ,
Participants With Moderately ,
Achieved Clinical Remission ,
Corticosteroid Free Remission Through ,
Ibd ,
Inflammatory Bowel Disease ,
Crohn Disease ,
Cd ,
Crohn X27s Disease ,
Guselkumab ,
Tremfya ,
Galaxi ,
Trial ,
Study ,
Remission ,
comparemela.com © 2020. All Rights Reserved.